<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01228903</url>
  </required_header>
  <id_info>
    <org_study_id>10-0625</org_study_id>
    <secondary_id>K23DK088833</secondary_id>
    <nct_id>NCT01228903</nct_id>
  </id_info>
  <brief_title>Uric Acid and the Endothelium in CKD</brief_title>
  <official_title>Is Uric Acid a Mediator of Endothelial Dysfunction in Patients With Chronic Kidney Disease?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the hypothesis that uric acid impairs the function of vessels in
      patients with kidney disease
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to understand the effect of lowering serum uric acid levels on
      vascular function in individuals with chronic kidney disease by comparing the effects of:

      1) Allopurinol therapy and 2) Placebo.

      Patients will receive: 3 month study drug (either allopurinol or placebo), with assessment of
      serum uric acid levels and vascular function.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Endothelial Dependent Dilation From Baseline to Week 12</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change in Endothelial Dependent Dilation measured by Flow Mediated Dilation at baseline and week 12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in C-reactive Protein From Baseline to Week 12</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Interleukin-6 From Baseline to Week 12</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Monocyte Chemotactic Protein-1 From Baseline to Week 12</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Oxidized Low Density Lipoprotein From Baseline to Week 12</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Serum Uric Acid Levels From Baseline to Week 12</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Serum uric acid levels were measured both at baseline and after 12 weeks</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients who are randomized to this group will received placebo tablets. Placebo tables do not contain an active ingredient. This group will be used as a baseline group to compare the effects of lowering uric acid on vascular function.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Allopurinol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who are randomized to this group will receive allopurinol tablets. Allopurinol is a medicine that lowers uric acid levels. The effects of lowering uric acid on vascular function outcomes will be assessed and compared to the control group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinol</intervention_name>
    <description>Xanthine oxidase inhibitor- effective at lowering uric acid levels.</description>
    <arm_group_label>Allopurinol</arm_group_label>
    <other_name>Zyloprim, Allohexal, Allosig, Milurit, Alloril, Progout, Zyloric.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets with no active ingredient</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals with moderate chronic kidney disease (CKD stage III) with estimated
             glomerular filtration rates between 30-60 mL/min/ 1.73m2

          -  Elevated uric acid levels

          -  Age range: more than 18 years old

          -  Ability to give informed consent

          -  Albumin &gt; 3.0 g/dL

          -  BMI &lt; 40 kg/m2

        Exclusion Criteria:

          -  Life expectancy &lt; 1.0 years

          -  Expected to undergo living related kidney transplant in 6 months

          -  Pregnant, breast feeding, or unwilling to use adequate birth control

          -  History of severe liver disease

          -  History of severe congestive heart failure

          -  History of hospitalizations within 3 months

          -  Active infection, on antibiotics

          -  History of Warfarin Use or other medications that are contraindicated with allopurinol

          -  Uncontrolled hypertension

          -  History of acute gout on Allopurinol

          -  History of adverse reaction to Allopurinol

          -  Immunosuppressive therapy within the last 1 yr
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diana Jalal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado at Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.drugs.com/pro/allopurinol.html</url>
    <description>Official information for Allopurinol</description>
  </link>
  <link>
    <url>http://www.ucdenver.edu/academics/colleges/medicalschool/departments/pediatrics/research/programs/ctrc/Pages/CTRC.aspx</url>
    <description>Information about the Recruiting Center</description>
  </link>
  <link>
    <url>http://en.wikipedia.org/wiki/Endothelium</url>
    <description>What is the endothelium?</description>
  </link>
  <link>
    <url>http://www.kidney.org/kidneydisease/ckd/index.cfm</url>
    <description>Facts about Kidney Disease</description>
  </link>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2010</study_first_submitted>
  <study_first_submitted_qc>October 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2010</study_first_posted>
  <results_first_submitted>October 24, 2016</results_first_submitted>
  <results_first_submitted_qc>January 3, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">February 23, 2017</results_first_posted>
  <last_update_submitted>June 9, 2017</last_update_submitted>
  <last_update_submitted_qc>June 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>uric acid kidney disease endothelial dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Allopurinol</mesh_term>
    <mesh_term>Uric Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified data will be made available to investigators upon request from the PI</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Control</title>
          <description>Patients who are randomized to this group will received placebo tablets. Placebo tables do not contain an active ingredient. This group will be used as a baseline group to compare the effects of lowering uric acid on vascular function.
Placebo: Placebo tablets with no active ingredient</description>
        </group>
        <group group_id="P2">
          <title>Allopurinol</title>
          <description>Patients who are randomized to this group will receive allopurinol tablets. Allopurinol is a medicine that lowers uric acid levels. The effects of lowering uric acid on vascular function outcomes will be assessed and compared to the control group.
Allopurinol: Xanthine oxidase inhibitor- effective at lowering uric acid levels.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control</title>
          <description>Patients who are randomized to this group will received placebo tablets. Placebo tables do not contain an active ingredient. This group will be used as a baseline group to compare the effects of lowering uric acid on vascular function.
Placebo: Placebo tablets with no active ingredient</description>
        </group>
        <group group_id="B2">
          <title>Allopurinol</title>
          <description>Patients who are randomized to this group will receive allopurinol tablets. Allopurinol is a medicine that lowers uric acid levels. The effects of lowering uric acid on vascular function outcomes will be assessed and compared to the control group.
Allopurinol: Xanthine oxidase inhibitor- effective at lowering uric acid levels.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="41"/>
            <count group_id="B2" value="39"/>
            <count group_id="B3" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.9" spread="9.3"/>
                    <measurement group_id="B2" value="55.9" spread="13.7"/>
                    <measurement group_id="B3" value="57.4" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Endothelial Dependent Dilation From Baseline to Week 12</title>
        <description>Change in Endothelial Dependent Dilation measured by Flow Mediated Dilation at baseline and week 12</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Placebo: Placebo tablets with no active ingredient</description>
          </group>
          <group group_id="O2">
            <title>Allopurinol</title>
            <description>Allopurinol: Xanthine oxidase inhibitor</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Endothelial Dependent Dilation From Baseline to Week 12</title>
          <description>Change in Endothelial Dependent Dilation measured by Flow Mediated Dilation at baseline and week 12</description>
          <units>% change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="4.1"/>
                    <measurement group_id="O2" value="0.9" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was the there will be no difference between the placebo and allopurinol. The power for the study was calculated (as appropriate) based on the prior literature.</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>(Doehner et al.) CHF patients on allopurinol (n= 14) had improved BA-FMD= 10.6 ± 2.0 (mean ± SE) vs placebo (n= 14, FMD= 6.7 ± 0.1); difference in means= 3.9. Yiginer et al. found a similar difference in metabolic syndrome. A sample size of 34/group will have 80% power to detect a difference in means of 3.9 (common standard deviation=5.6, two group t-test=0.050 two-sided significance). Accounting for a potential drop-out rate17%, n= 40/group was recruited.</non_inferiority_desc>
            <p_value>0.47</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.7</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>The estimated value represents the difference between the change from baseline in both groups.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in C-reactive Protein From Baseline to Week 12</title>
        <time_frame>Baseline and 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Placebo: Placebo tablets with no active ingredient</description>
          </group>
          <group group_id="O2">
            <title>Allopurinol</title>
            <description>Allopurinol: Xanthine oxidase inhibitor</description>
          </group>
        </group_list>
        <measure>
          <title>Change in C-reactive Protein From Baseline to Week 12</title>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="3.4"/>
                    <measurement group_id="O2" value="00.42" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Interleukin-6 From Baseline to Week 12</title>
        <time_frame>Baseline and 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Placebo: Placebo tablets with no active ingredient</description>
          </group>
          <group group_id="O2">
            <title>Allopurinol</title>
            <description>Allopurinol: Xanthine oxidase inhibitor</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Interleukin-6 From Baseline to Week 12</title>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="3.1"/>
                    <measurement group_id="O2" value="0.37" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Monocyte Chemotactic Protein-1 From Baseline to Week 12</title>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>-4.7</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Placebo: Placebo tablets with no active ingredient</description>
          </group>
          <group group_id="O2">
            <title>Allopurinol</title>
            <description>Allopurinol: Xanthine oxidase inhibitor</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Monocyte Chemotactic Protein-1 From Baseline to Week 12</title>
          <population>-4.7</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.7" spread="45.8"/>
                    <measurement group_id="O2" value="3.6" spread="36.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Oxidized Low Density Lipoprotein From Baseline to Week 12</title>
        <time_frame>Baseline and 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Placebo: Placebo tablets with no active ingredient</description>
          </group>
          <group group_id="O2">
            <title>Allopurinol</title>
            <description>Allopurinol: Xanthine oxidase inhibitor</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Oxidized Low Density Lipoprotein From Baseline to Week 12</title>
          <units>u/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="11.8"/>
                    <measurement group_id="O2" value="-2.97" spread="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Serum Uric Acid Levels From Baseline to Week 12</title>
        <description>Serum uric acid levels were measured both at baseline and after 12 weeks</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Placebo: Placebo tablets with no active ingredient</description>
          </group>
          <group group_id="O2">
            <title>Allopurinol</title>
            <description>Allopurinol: Xanthine oxidase inhibitor</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Uric Acid Levels From Baseline to Week 12</title>
          <description>Serum uric acid levels were measured both at baseline and after 12 weeks</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="1.54"/>
                    <measurement group_id="O2" value="3.24" spread="1.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Control</title>
          <description>Patients who are randomized to this group will received placebo tablets. Placebo tables do not contain an active ingredient. This group will be used as a baseline group to compare the effects of lowering uric acid on vascular function.
Placebo: Placebo tablets with no active ingredient</description>
        </group>
        <group group_id="E2">
          <title>Allopurinol</title>
          <description>Patients who are randomized to this group will receive allopurinol tablets. Allopurinol is a medicine that lowers uric acid levels. The effects of lowering uric acid on vascular function outcomes will be assessed and compared to the control group.
Allopurinol: Xanthine oxidase inhibitor- effective at lowering uric acid levels.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>One patient died in the allopurinol arm, and it was attributed to a cardiovascular event</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal Liver Function Tests</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>gout</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Diana Jalal</name_or_title>
      <organization>University of Colorado</organization>
      <phone>3037244867</phone>
      <email>diana.jalal@ucdenver.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

